As a newly defined tumor-suppressive pathway, the LRP5/LIMA1/MYO5B axis provides a mechanistic basis and potential therapeutic targets for breaking the “vicious cycle” between tumor cells and the bone microenvironment, thereby offering a promising strategy for the prevention and treatment of breast cancer bone metastasis. This evidence concerns the gene LRP5 and neoplasm.